Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Yahoo Finance1h
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small ...
FierceBiotech1d
BioNTech pays $800M to take control of potential Keytruda killer
Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...
Cure Today1d
Jemperli-Chemo Regimen Shows Survival Promise in Advanced NSCLC
Jemperli plus chemotherapy demonstrated superior overall survival ... Keytruda group. A first-line treatment combination of ...
UVA Today1d
Q&A: What’s Going on With Lung Cancer Research?
Other causes of lung cancer are well known, like radon gas exposure, which happens to be fairly prevalent in Appalachia. It’s ...
Targeted Oncology5d
Adjuvant/Neoadjuvant Therapies Are Addressed in Lung Cancer
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
precisionmedicineonline5d
Arcus Confident in Anti-TIGIT, Immunotherapy, Chemo Regimen After Seeing Phase II Survival Data
The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.
American Lung Association6d
Lung Cancer Screening Assistance
50 – 80 years of age Have a 20 pack-year history of smoking (1 pack a day for 20 years or 2 packs a day for 10 years) Are a current smoker or have quit within the last 15 years If you meet the ...